Suppr超能文献

在 PDE5 抑制剂时代,阴茎海绵体内注射治疗在勃起功能障碍患者中的作用及停药原因。

The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.

机构信息

Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Andrology. 2014 Jan;2(1):45-50. doi: 10.1111/j.2047-2927.2013.00155.x. Epub 2013 Nov 6.

Abstract

There has been little data regarding the role of intracavernosal injection (ICI) treatment, its discontinuation rate and the reasons of withdrawal in patients with erectile dysfunction (ED) in the era of phosphodiesterase type 5 (PDE5) inhibitors. The aim of this study was to investigate the rate of withdrawal and its associated reasons in patients undergoing ICI therapy. Patients who were prescribed with ICI treatment two times or more were included since the introduction of sildenafil in Korea in 1999. Telephone surveys were performed to evaluate intercourse rates, withdrawal rates and their associated reasons, adverse events and the patients' satisfaction with their sex lives after the ICI treatments. Two hundred and ninety-four men were contacted by telephone. The mean age was 61.8 ± 7.9 years with a follow-up duration of 25.6 ± 32.1 months. At the last follow-up, 79.9% had discontinued the treatment. Most patients had previously failed PDE5 inhibitor treatment prior to the ICI therapy, and more than half had two or more risk factors of ED. Adequate penile rigidity after ICI therapy was restored in 60.2% of patients. The reasons for discontinuation of ICI were poor response (43.1%), inconvenience of use (18.3%), switch to other treatments (10.7%), loss of libido (6.7%), adverse events (5.5%) and return of spontaneous erection (2.8%). Pain was the most common adverse event in the withdrawal group, whereas prolonged erection was most common in the continuing group. Following ICI treatment, PDE5 inhibitors were the most common therapeutic option (63.1%). The overall satisfaction rate regarding sex life was significantly high in the treatment-continuing group. In conclusion, patients on ICI treatment had severe ED and high withdrawal rates in the era of PDE5 inhibitors. The most common reason for treatment discontinuation was poor response. Before initiating ICI treatments, sufficient counselling is necessary.

摘要

关于磷酸二酯酶 5 (PDE5) 抑制剂时代阴茎海绵体内注射 (ICI) 治疗的作用、停药率和停药原因,目前相关数据较少。本研究旨在调查接受 ICI 治疗的患者停药率及其相关原因。自 1999 年西地那非在韩国上市以来,纳入接受 ICI 治疗两次或以上的患者。通过电话调查评估性交频率、停药率及其相关原因、不良反应以及患者接受 ICI 治疗后的性生活满意度。通过电话联系了 294 名男性。平均年龄为 61.8 ± 7.9 岁,随访时间为 25.6 ± 32.1 个月。最后一次随访时,79.9%的患者已停止治疗。大多数患者在接受 ICI 治疗前曾接受过 PDE5 抑制剂治疗失败,超过一半的患者有 2 个或更多的 ED 危险因素。60.2%的患者在接受 ICI 治疗后阴茎勃起硬度恢复良好。停止 ICI 的原因是疗效不佳 (43.1%)、使用不便 (18.3%)、改用其他治疗方法 (10.7%)、性欲减退 (6.7%)、不良反应 (5.5%)和自发性勃起恢复 (2.8%)。疼痛是停药组最常见的不良反应,而持续组最常见的是勃起持续时间延长。在接受 ICI 治疗后,PDE5 抑制剂是最常见的治疗选择 (63.1%)。继续治疗组对性生活的总体满意度显著较高。总之,在 PDE5 抑制剂时代,接受 ICI 治疗的患者 ED 严重且停药率高。最常见的停药原因是疗效不佳。在开始 ICI 治疗前,需要进行充分的咨询。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验